The Role of Clinical Pharmacist in Management of DDIs in CHF Patients

The University Clinic of Pulmonary and Allergic Diseases Golnik

Status: Unknown

Conditions: Chronic Heart Failure

Treatments: Behavioral: Advice on DDIs

Study type: Interventional

Funder types: Other

Identifiers

NCT01855165

CHF42013

109/01/13 (Other Identifier)

Details and patient eligibility

About

Drug-drug interactions (DDIs) are common in patients with chronic heart failure (CHF) and their incidence increases with the number of drugs that the patients are prescribed for treatment of their condition. Data bases often detect DDIs that are of high clinical relevance. The investigators have performed this study in order to detect clinically significant DDIs and to diminish their occurrence by sending notification about DDIs to attending physician.

Enrollment: 60 estimated patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients admitted with diagnosis of CHF I50.0 - I50.9 and I11.0 - I11.9 (ICD-10)
• patients treated with at least two drugs

Exclusion criteria

• Patients admitted to other conditions

Trial design

Primary purpose: Health Services Research

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

60 participants in 2 patient groups

Advice on DDIs

Experimental group

Description:

Attending physician will be randomly assigned to intervention arm care as usual; in the intervention arm, he/she will receive advice about DDIs between medications prescribed to patients on top of general heart failure advice.

Treatment:

Behavioral: Advice on DDIs

General advice

No Intervention group